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Objective: Chronic kidney disease is associated with decreased bone mineral density (BMD). In this study,
the relationship between BMD and the fasting serum concentration of N-terminal pro-B-type natriuretic
peptide (NT-pro-BNP) was evaluated in peritoneal dialysis (PD) patients.
Material and Methods: Fasting blood samples were obtained from 52 PD patients. BMD was measured by
dual energy X-ray absorptiometry of the lumbar vertebrae (L2eL4). The serum NT-pro-BNP level was
measured by an electrochemiluminescence immunoassay.
Results: Ten patients (19.2%) had osteoporosis, 23 patients (44.2%) had osteopenia, and 19 patients had
normal BMD. Increased serum NT-pro-BNP (p < 0.001), advanced age (p ¼ 0.012), decreased body mass
index (p ¼ 0.006), body height (p ¼ 0.018), and body weight (p ¼ 0.004) were associated with lower
lumbar T-scores, but sex, menopausal status, PD modality, diabetes mellitus, and hypertension were not.
Multivariate forward stepwise linear regression analysis with adjustment for age, body height, body
weight, body mass index, and log-NT-pro-BNP indicated that a high serum level of log-NT-pro-BNP (R2
change ¼ 0.346; p < 0.001) and low body weight (R2 change ¼ 0.208; p < 0.001) were signiﬁcantly and
independently associated with poor lumbar BMD.
Conclusion: A high serum level of NT-pro-BNP and low body weight were associated with poor BMD in
PD patients.
Copyright © 2016, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is the
inactive amino terminal fragment that is a cleavage product of pro-
BNP. It is secreted by the heart along with biologically active BNP,
and is one of the natriuretic peptides [1]. Recent studies have
shown that elevated serum NT-pro-BNP is an independent pre-
dictor of adverse outcomes from congestive heart failure [2]. InBuddhist Tzu Chi General
aiwan. Tel.: þ886 3 8561825;
.
lief Tzu Chi Foundation. Publishedhemodialysis patients, elevated serum NT-pro-BNP is associated
with hypervolemia and mortality [3,4].
Bone mineral density (BMD), an indication of bone mass and
mineralization, is one of the major determinants of bone strength
[5]. Several factors can affect bone metabolism, including age, sex,
activity of the renineangiotensin system (RAS), and the levels of
adipokines [6,7]. The natriuretic peptides inhibit the RAS and are
potent lipolytic agents that act in adipose tissue and inﬂuence BMD
[8e10]. There is a high prevalence of reduced bone mass or BMD
such as osteopenia and osteoporosis in the general population and
it is common in patients with chronic kidney disease (CKD) and
those on maintenance dialysis [11,12]. Previous research has shown
that reduced BMD in hemodialysis patients is associated with an
increased prevalence of osteoporosis in the mid-radius (50e80%),
femoral neck (16e47%), lumbar spine (13e29%), and the total bodyby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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ported a prevalence of osteoporosis of 19.5% in the lumbar spine
and 26% in the femoral neck based on T-scores [13]. In the presence
of osteoporosis or osteopenia, bone mineral loss in PD patients was
as high as 56% [13]. Another study reported that lower BMD was
associated with worse outcomes in dialysis patients [11].
Our previous study found that the serum concentration of long-
acting natriuretic peptide was negatively associated with lumbar
BMD in renal transplant recipients [14]. However, no studies have
examined the relationship of lumbar BMD with the serum level of
NT-pro-BNP in PD patients. The aim of this study was to determine
the relationship between the serum NT-pro-BNP concentration and
lumbar BMD in PD patients.
2. Materials and methods
2.1. Patients
The Protection of Human Subjects Institutional Review Board of
Tzu Chi University and Hospital approved this prospective study
(IRB098-63), and all participants provided informed consent. Fifty-
two PD patients at Tzu-Chi General Hospital (Hualien, Taiwan)were
enrolled in March 2010. This group consisted of 20 men and 32
women (17 of whomwere postmenopausal), and the age rangewas
19e73 years. The exclusion criteria were acute infection, malig-
nancy, acute myocardial infarction, pulmonary edema, heart failure
at the time of blood sampling, use of osteoporosis drugs
(bisphosphonates, teriparatide, or estrogenmedications), or history
of lumbar fracture or surgery. Theweekly fractional clearance index
for urea (weekly Kt/V), total clearance (peritoneal clearance added
to residual clearance), and creatinine clearance (Clcr) were ob-
tained from medical record.
2.2. Anthropometric analysis
Body weight was measured to the nearest half kg with the pa-
tient in light clothing without shoes. Height was measured to the
nearest half centimeter. Body mass index (BMI) was calculated as
the weight (kg) divided by height squared (m2) [14e16].
2.3. Biochemical determinations
Fasting blood samples (approximately 5 mL) were immediately
centrifuged at 3000 g for 10 minutes after collection. Serum sam-
ples were stored at 4C and used for biochemical analyses within
1 h of collection. Serum levels of creatinine fasting glucose, total
cholesterol, triglycerides, high-density lipoprotein-cholesterol, al-
bumin, globulin, total calcium, and phosphorus were measured
using an autoanalyzer (COBAS Integra 800, Roche Diagnostics,
Basel, Switzerland). Serum samples were assayed for NT-pro-BNP
by an electrochemiluminescence immunoassay on the Elecsys
2010 Immunoanalyzer (Roche Diagnostics, Indianapolis, IN, USA)
[15,16]. Serum intact parathyroid hormone (iPTH; Diagnostic Sys-
tems Laboratories, Webster, Texas, USA) was measured using a
commercially available enzyme-linked immunosorbent assay [14].
2.4. BMD measurements
After blood sampling, patients were immediately given BMD
measurements. The BMD in the lumbar vertebrate (L2eL4) was
measured using dual energy X-ray absorptiometry (QDR 4500,
Hologic Inc., Bedford, MA, USA). BMD is expressed as an absolute
value (g/cm2), as a Z-score, and as a T-score (deviation from peak
BMD) [14]. The Z-score was deﬁned as the number of standard
deviations from the mean BMD of age-, weight-, and ethnicity-matched healthy individuals. The T-score was deﬁned as the
number of standard deviations from themean BMD of sex-matched
young control individuals. Compared with the control value, a
lumbar bone T-score < 2.5 was used as the diagnostic cut-off for
osteoporosis and a lumbar bone T-score of 1.0 to 2.5, was used
for a diagnosis of osteopenia, according to World Health Organi-
zation criteria [14].2.5. Statistical analysis
Data were tested for normal distribution using the Kolmogor-
oveSmirnov test. Data were expressed as means ± standard devi-
ation for normally distributed data and as medians and
interquartile ranges for non-normally distributed data. The glucose,
iPTH, NT-pro-BNP, total clearance, and Clcr datasets showed
skewed non-normal distributions and therefore these were recal-
culated by transformation to the base 10 logarithm; after this
transformation the log-glucose, log-iPTH, log-NT-pro-BNP, log-total
clearance, and log-Clcr then became normally distributed. The
signiﬁcance of differences between groups (normal, osteopenia,
and osteoporosis) was determined using the KruskaleWallis test
for parameters that had non-normal distributions and by one-way
analysis of variance for normally distributed data. Comparisons
between patients were performed using Student independent t test
(2-tailed) for normally distributed data. Clinical variables that
correlated with lumbar BMD in PD patients were evaluated by
univariable linear regression analysis. Variables that were signiﬁ-
cantly associated with lumbar BMD in PD patients were tested for
independence by multivariate forward stepwise regression anal-
ysis. All statistical analyses employed SPSS for Windows (version
19.0; SPSS Inc., Chicago, IL, USA). A p-value < 0.05 was considered
statistically signiﬁcant.3. Results
Table 1 shows the anthropometric and biochemical data of all 52
PD patients, and Table 2 shows the age and clinical characteristics
of the three bone density groups (normal, osteopenia, and osteo-
porosis). Ten patients (19.2%) had osteoporosis, 23 patients (44.2%)
had osteopenia, and 19 patients (36.5%) had normal BMD. The re-
sults show that older age (p ¼ 0.012), decreased height (p ¼ 0.018),
low BMI (p ¼ 0.006), low body weight (p ¼ 0.004), and elevated
serum NT-pro-BNP (p < 0.001) were signiﬁcantly associated with
poor BMD (low lumbar T-score).
Table 3 shows the clinical characteristics and lumbar BMD (g/
cm2) of all 52 PD patients. The results show that lumbar BMD was
not signiﬁcantly affected by sex, presence of diabetes mellitus
(DM), hypertension, smoking, mode of PD, or menopausal status.
Moreover, the NT-pro-BNP values were not signiﬁcantly associated
with sex, presence of DM, hypertension, smoking, menopausal
status, or mode of PD (data not shown).
Univariable linear analysis of the lumbar BMD in the 52 PD
patients is presented in Table 4. Height (r ¼ 0.332, p ¼ 0.016), body
weight (r ¼ 0.570, p < 0.001), and BMI (r ¼ 0.537, p < 0.001) was
positively correlated, while age (r¼0.320, p¼ 0.021), and log-NT-
pro-BNP (r ¼ 0.589, p < 0.001) were negatively correlated with
lumbar BMD in the 52 PD patients.
Table 5 shows the results of a multivariate forward stepwise
linear regression analysis of the relationship of age, height, body
weight, BMI, and log-NT-pro-BNP with BMD. These results show a
signiﬁcant and independent association of lumbar BMD with the
level of log-NT-pro-BNP (R2 change ¼ 0.346, p < 0.001) and body
weight (R2 change ¼ 0.208, p < 0.001).
Table 1
Anthropometric and biochemical data of the 52 peritoneal dialysis patients.
Items Parameter Parameter
Anthropometric data Height (cm) 159.32 ± 8.51 Age (y) 52.85 ± 13.16
Body weight (kg) 62.30 ± 13.86 PD duration (mo) 41.79 ± 37.35
Body mass index (kg/m2) 24.37 ± 4.15 SBP (mmHg) 134.04 ± 24.00
DBP (mmHg) 77.25 ± 15.85 Lumbar T-score 1.42 ± 1.30
Lumbar T-score 0.90 ± 0.84 Lumbar BMD (g/cm2) 0.66 ± 0.15
Biochemical data Albumin (g/dL) 3.83 ± 0.44 Globulin (g/dL) 2.94 ± 0.54
Triglyceride (mg/dL) 209.06 ± 134.13 Total cholesterol (mg/dL) 194.60 ± 51.62
HDL-C (mg/dL) 43.96 ± 13.73 Creatinine (mg/dL) 10.24 ± 3.03
Fasting glucose (mg/dL) 94.50 (86.00e110.00) Total Calcium (mg/dL) 9.66 ± 0.66
Phosphorus (mg/dL) 5.27 ± 1.20 Ca  P product (mg2/dL2) 50.92 ± 11.96
iPTH (pg/mL) 291.7 (157.53e605.18) NT-pro-BNP (pg/mL) 2035.50 (1223.00e5303.25)
Weekly Kt/V 2.03 ± 0.40 Total clearance (L/week) 54.28 (48.51e70.23)
Clcr (mL/min) 0.94 (0.00e3.38)
Values for continuous variables given as means ± standard deviation; variables not normally distributed given as medians and interquartile range.
BMD ¼ bone mineral density; Clcr ¼ creatinine clearance; DBP ¼ diastolic blood pressure; HDL-C ¼ high density lipoprotein cholesterol; iPTH ¼ intact parathyroid hormone;
Kt/V ¼ fractional clearance index for urea; NT-pro-BNP¼N-terminal pro-B-type natriuretic peptide; PD ¼ peritoneal dialysis; SBP ¼ systolic blood pressure.
Table 2
Clinical characteristics of the 52 peritoneal dialysis patients with different lumbar T-scores.
Characteristic Normal (n ¼ 19)
T-score > 1
Osteopenia (n ¼ 23)
2.5 < T-score  1
Osteoporosis (n ¼ 10)
T-score  2.5
p
Age (y) a 47.47 ± 12.81 53.13 ± 13.09 62.40 ± 8.46 0.012*
Peritoneal dialysis duration (mo) a 47.00 ± 37.46 37.78 ± 34.55 41.10 ± 45.62 0.735
Height (cm) a 160.16 ± 8.65 161.50 ± 7.22 152.70 ± 8.42 0.018*
Body weight (kg) a 68.46 ± 14.14 62.08 ± 12.95 51.11 ± 7.69 0.004*
Body mass index (BMI; kg/m2) a 26.54 ± 4.29 23.68 ± 3.93 21.85 ± 2.17 0.006*
Lumbar T-score a 0.10 ± 0.95 1.77 ± 0.42 3.12 ± 0.39 < 0.001*
Lumbar Z-score a 0.08 ± 0.84 1.05 ± 0.47 1.93 ± 0.59 < 0.001*
Lumbar bone density mass (g/cm2) a 0.79 ± 0.12 0.64 ± 0.07 0.46 ± 0.05 < 0.001*
Albumin (g/dL) a 4.01 ± 0.38 3.76 ± 0.40 3.68 ± 0.58 0.095
Globulin (g/dL) a 2.88 ± 0.61 2.97 ± 0.53 3.00 ± 0.47 0.829
Total cholesterol (mg/dL) a 208.89 ± 64.01 189.43 ± 35.68 179.30 ± 55.09 0.282
Triglyceride (mg/dL) a 255.05 ± 160.02 176.04 ± 122.74 197.60 ± 80.68 0.158
High density lipoprotein (HDL; mg/dL) a 42.73 ± 15.06 42.74 ± 10.41 49.10 ± 17.70 0.428
Fasting glucose (mg/dL) b 117.00 (95.00e179.00) 104.00 (91.00e159.00) 115.50 (104.00e256.25) 0.303
Creatinine (mg/dL) a 10.92 ± 3.63 10.38 ± 2.74 8.63 ± 1.78 0.146
Total calcium (mg/dL) a 9.51 ± 0.73 9.73 ± 0.62 9.76 ± 0.63 0.509
Phosphorus (mg/dL) a 5.57 ± 0.95 5.32 ± 1.15 4.62 ± 1.60 0.125
Ca  P product (mg2/dL2) a 53.02 ± 10.08 15.92 ± 12.24 44.63 ± 13.63 0.174
Intact parathyroid hormone (pg/mL) b 220.20 (142.40e527.30) 375.80 (184.40e815.10) 271.10 (124.50e396.98) 0.199
NT-pro-BNP (pg/mL) b 1223.00 (879.00e1794.00) 2772.00 (1780.00e4216.00) 5733.00 (5367.00e6179.00) < 0.001*
Systolic blood pressure (mmHg) a 137.79 ± 26.14 135.61 ± 20.83 123.30 ± 25.92 0.282
Diastolic blood pressure (mmHg) a 77.21 ± 17.90 80.65 ± 16.46 69.50 ± 9.66 0.180
Weekly Kt/V a 2.06 ± 0.42 2.07 ± 0.43 1.88 ± 0.27 0.428
Total clearance (L/week) 62.27 (46.98e77.45) 52.95 (50.36e78.99) 54.19 (42.28e61.53) 0.327
Clcr (mL/min) 0.9 (0.00e5.09) 0.97 (0.00e3.09) 1.00 (0.00e2.77) 0.881
BMD ¼ bone mineral density; Clcr ¼ creatinine clearance; HDL-C ¼ high-density lipoprotein-cholesterol; Kt/V ¼ fractional clearance index for urea; LDL-C ¼ low-density
lipoprotein-cholesterol; NT-pro-BNP¼N-terminal pro-B-type natriuretic peptide.
a Data tested by one-way analysis of variance.
b Data tested by KruskaleWallis analysis; * p < 0.05 was considered statistically signiﬁcant after KruskaleWallis analysis or one-way analysis of variance (ANOVA).
Table 3
Clinical characteristics and lumbar bone mineral density levels of the 52 peritoneal
dialysis patients.
Characteristic Number (%) Lumbar BMD (g/cm2) p
Sex Male 20 (38.5) 0.68 ± 0.17 0.394
Female 32 (61.5) 0.64 ± 0.14
DM No 32 (61.5) 0.65 ± 0.13 0.563
Yes 20 (38.5) 0.67 ± 0.18
Hypertension No 21 (40.3) 0.67 ± 0.14 0.741
Yes 31 (59.7) 0.65 ± 0.15
PD model CAPD 43 (82.7) 0.66 ± 0.14 0.975
APD 9 (17.3) 0.66 ± 0.19
Smoking No 42 (80.7) 0.65 ± 0.15 0.262
Yes 10 (19.3) 0.71 ± 0.13
Menopause No 15 (47.9) 0.69 ± 0.13 0.081
Yes 17 (51.1) 0.60 ± 0.13
*p < 0.05 was considered statistically signiﬁcant after the Student's independent t
test.
APD ¼ ambulatory peritoneal dialysis; CAPD ¼ continuous ambulatory peritoneal
dialysis; DM ¼ diabetes mellitus; PD ¼ peritoneal dialysis.
C.-H. Wang et al. / Tzu Chi Medical Journal 28 (2016) 68e72704. Discussion
The major results of this study of 52 PD patients are that body
weight had a signiﬁcant and independent positive association with
lumbar BMD, and that the fasting serum level of NT-pro-BNP had a
signiﬁcant and independent negative association with lumbar
BMD. In addition, analysis of the three deﬁned bone density groups
(normal, osteopenia, and osteoporosis) indicated that an increased
serum NT-pro-BNP level was signiﬁcantly correlated with a low
lumbar T-score.
Disorders of bone metabolism are common in patients with
CKD, and bone strength declines more severely as CKD progresses
than during the normal aging process [5,17]. Abnormal bone
strength can cause musculoskeletal pain, negatively impact quality
of life, and increase the risk for bone fracture [17]. A study of PD
patients in Poland indicated that many patients had osteoporosis
(15.4%) and osteopenia (38.5%) in the femoral neck [17]. Similarly, a
study of PD patients in Korea indicated that osteoporosis of the
Table 4
Correlation of lumbar bone mineral density levels and clinical variables by univar-
iate linear regression analysis among the 52 peritoneal dialysis patients.
Variable R value p
Age 0.320 0.021*
Peritoneal dialysis duration 0.017 0.906
Height 0.332 0.016*
Body weight 0.570 < 0.001*
Body mass index 0.537 < 0.001*
Albumin 0.265 0.058
Globulin 0.093 0.513
Total cholesterol 0.096 0.497
Triglyceride 0.132 0.352
High density lipoprotein 0.244 0.081
Log-glucose 0.060 0.672
Creatinine 0.257 0.065
Total calcium 0.127 0.368
Phosphorus 0.254 0.069
Ca  P product 0.217 0.123
Log-intact parathyroid hormone 0.022 0.877
Log-NT-pro-BNP 0.589 < 0.001*
Systolic blood pressure 0.223 0.112
Diastolic blood pressure 0.120 0.398
Weekly Kt/V 0.095 0.504
Log-total clearance 0.260 0.062
Log-Clcr 0.190 0.289
Data of glucose, iPTH, NT-pro-BNP, total clearance, and Clcr levels showed skewed
distribution, and therefore were log-transformed before analysis; *p < 0.05 is
considered statistically signiﬁcant in the univariate linear analyses.
Clcr ¼ creatinine clearance; Kt/V ¼ fractional clearance index for urea; NT-pro-
BNP¼N-terminal pro-B-type natriuretic peptide.
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femoral neck (53%) and lumbar spine (41%) were common [18]. Our
previous study also indicated that lumbar spine osteoporosis
(11.6%) and osteopenia (40.6%) were common in renal transplant
recipients [14]. In the present study, 19.2% of Taiwanese PD patients
had osteoporosis and 44.2% had osteopenia of the lumbar spine.
Traditional risk factors, such as advanced age, female sex,
hormonal factors, decreased physical activity, thin body habitus,
cigarette smoking, alcohol abuse, and possibly some genetic fac-
tors increase the risk for osteoporosis [12]. In addition to these
traditional risk factors for low BMD, patients with CKD have
additional risk factors, including hyperparathyroidism, 1,25-
dihydroxyvitamin D deﬁciency, use of immunosuppression ther-
apy, chronic metabolic acidosis, secondary amenorrhea, and hep-
arin exposure (in dialyzed patients) [19,20]. In the present study,
we found no signiﬁcant effect of sex, smoking, menopause, DM,
hypertension, or modality of PD on BMD in PD patients. Univariate
analysis indicated that advanced agewas associated with BMD, but
this factor was not signiﬁcantly associated with BMD in multi-
variate analysis.
Low BMI is a known risk factor for osteoporosis [21], and loss of
BMD is a common complication that correlates with low body
weight and low BMI in renal transplantation recipients [22]. Our
previous study of renal transplant recipients indicated that bodyTable 5
Multivariate stepwise linear regression analysis of the association of age, height,
body weight, body mass index, and log-NT-pro-BNP with lumbar bone mineral
density in 52 peritoneal dialysis patients.
Items b R2 R2 change Adjusted R2 p
Log-NT-pro-BNP 0.490 0.346 0.346 0.333 < 0.001*
Body weight 0.467 0.554 0.208 0.203 < 0.001*
*p < 0.05 is considered statistically signiﬁcant in the multivariate stepwise linear
regression analysis.
NT-pro-BNP¼N-terminal pro-B-type natriuretic peptide.height, body weight, and BMI were positively correlated with
lumbar BMD [14]. In addition, Atsumi et al indicated an inverse
relationship between body weight and osteoporosis in patients
undergoing hemodialysis [23], and Jeong el al reported that nutri-
tional markers such as age, BMI, albumin, and prealbumin were
independent predictors of femoral neck T-scores and BMI as a
predictor of L-spine T-scores [18]. Ersoy et al [13] studied 292 PD
patients and found that BMI was strongly correlated with BMD.
They postulated that the factor most responsible for this strong
statistical correlation was patient weight rather than height [13].
Similarly, our multivariate analysis indicated that body weight was
positively correlated with BMD in PD patients.
A previous study of dialysis patients reported that NT-pro-BNP
was associated with increased left ventricular mass and ejection
fraction, and was a better predictor of 3-month to 5-year mortality
than high sensitivity C-reactive protein or cardiac troponin T [24].
However, few studies have examined the association of NT-pro-
BNP with BMD in dialysis patients. A study of transgenic mice
indicated that activation of the RAS induced osteoporosis inde-
pendently of hypertension [25], and a study of a hypertensive rat
model indicated that inhibitors of the RAS attenuated osteoporosis
[26]. Clinical studies also reported that administration of
angiotensin-converting enzyme inhibitors increased BMD [27,28].
Natriuretic peptide inhibits the RAS axis by binding its common
receptor, guanylyl cyclase-A, which leads to activation through a
cyclic guanosinemonophosphate (cGMP)-dependent pathway [10].
In addition, natriuretic peptides are potent lipolytic agents that act
in adipose tissue via the BNPecGMP-dependent protein kinase
cascade, which increases fat oxidation [8,29]. Body weight is a
function of fat mass and leanmass, and could impact bone turnover
and bone density [30,31]. Thus, the pathophysiological relevance of
natriuretic peptide in bone integrity may be explained by the
participation of adipokines in bone remodeling due to their effects
on bone deposition and resorption [31]. We previously found that
NT-pro-BNP levels were signiﬁcantly correlated with poor lumbar
T-scores and proposed that NT-pro-BNP plays a role in the regula-
tion of BMD [14]. In other words, there is a negative association
between natriuretic peptides and BMD in renal transplant re-
cipients [14]. In the present study, we also found that increased
serum NT-pro-BNP levels were associated with poor lumbar T-
scores and the serum level of NT-pro-BNP was a signiﬁcant and
independent predictor of lumbar BMD in PD patients.
The present study had some limitations. First, only a small
number of PD patients were enrolled, so the statistical power for
comparison of groups was weak. Second, this study had a cross-
sectional design, and did not employ a control group. Therefore,
the ﬁndings of this study must be conﬁrmed by long-term pro-
spective studies before a causal relationship between serum NT-
pro-BNP and BMD in PD patients can be established.
In conclusion, this study of PD patients from Taiwan indicated
that the fasting serum NT-pro-BNP level was negatively associated
and that body weight was positively associated with lumbar BMD.Acknowledgments
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